ReOL - OLaparib in the REal World. A retrospective observational study to evaluate the impact of olaparib on the real-world treatment of BRCA carrier patients with recurrent ovarian cancer

The main aim of this study was to evaluate the correlation between the effectiveness of olaparib in the maintenance setting and the number of previous chemotherapy lines received for the treatment of BRCA-mutated platinum-sensitive relapsed ovarian cancer (OC). This was a regional, multicentric, retrospective, and observational study, designed to collect data from medical charts of patients treated between June 2015 and October 2018. At data lock, 43 patients were evaluated for the study. Patients with 1-2 previous lines of platinum-based chemotherapy showed a higher response rate to olaparib, compared to those with 3-4 or more previous lines. No difference in terms of progression-free survival (PFS) was observed between the two groups; 40.5% of patients experienced a G3-4 adverse event, while no significant difference was observed between the two groups in terms of G3-4 toxicities. This is the first Italian study evaluating the use of olaparib in the “real-world” treatment of OC patients, offering a preliminary but useful picture of current clinical practice in Puglia region.

Olaparib; Ovarian cancer; BRCA; Real-world practice

[1] Dziadkowiec K.N., Gąsiorowska E., Nowak-Markwitz E., Jankowska A.: “PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting”. Menopause Rev., 2016, 15, 215.

[2] Gruppo di Lavoro AIOM-SIGU-SIBIOC-SIAPEC-IAP: “Raccomandazioni per l’implementazione del test BRCA nei percorsi assistenziali e terapeutici delle pazienti con carcinoma ovarico”, 2015.

[3] https://www.ema.europa.eu/en/medicines/human/EPAR/lynparza

[4] Ledermann J., Harter P., Gourley C., Friedlander M., Vergote I., Rustin G., et al.: “Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer”. N. Engl. J. Med., 2012, 366, 1382.

[5] Pujade-Lauraine E., Ledermann J.A., Selle F., Gebski V., Penson R.T., Oza A.M., et al.: “Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial”. Lancet Oncol., 2017, 18, 1274.

[6] Moore K., Colombo N., Scambia G., Kim B.G., Oaknin A., Friedlander M., et al.: “Maintenance Olaparib in Patients with Newly Diagnosed Advanced Ovarian Cancer”. N. Engl. J. Med., 2018, 379, 2495.

[7] https://www.aiom.it/wp-content/uploads/2018/11/2018_LG_AIOM_Ovaio.pdf

[8] “C-PATROL - Non-interventional Study (NIS) to Collect Clinical and Patient Reported Outcome Data in an Olaparib Treated BRCAm+ PSR Ovarian Cancer Population. (C-PATROL)”, https://clinicaltrials.gov/ct2/show/NCT02503436term=olaparib&ty pe=Obsr&cond=Ovarian+Cancer&rank=1

[9] Rafii S., Gourley C., Kumar R., Geuna E., Ang J.E., Rye T., et al.: “Baseline clinical predictors of antitumor response to the PARP inhibitor olaparib in germline BRCA1/2 mutated patients with advanced ovarian cancer” Oncotarget, 2017, 8, 47154.

[10] Gadducci A., Guarneri V., Peccatori F.A., Ronzino G., Scandurra G., Zamagni C., et al.: “Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status”. J. Ovarian Res., 2019, 12, 9.